Combo Products Collaboration Up To Industry, Not FDA – RAPS Summit
This article was originally published in The Pink Sheet Daily
Executive Summary
Although drug companies can be reluctant to partner with device firms on combo products, it is not FDA’s role to coerce firms to partner on cross-labeling development, participants at a Regulatory Affairs Professionals Society summit say. FDA will hold a meeting on cross-labeling in the spring.
You may also be interested in...
Pharma/Device Combination Product Incentives Under Consideration At FDA
User fee reductions or waivers and exclusivity incentives are tools at FDA’s disposal to make cooperating with device firms more attractive to pharmaceutical manufacturers. Such incentives may still be insufficient to draw pharma manufacturers’ interest, an agency attorney says.
ICMJE Clinical Trial Registration Criteria Could Exempt High-Risk Medical Devices, Says IoM Report
The Institute’s Board on Health Sciences Policy is preparing a clinical trials registry for fall release.